Is NCT07474090 recruiting in Richmond, VA?

Yes, NCT07474090 is currently recruiting participants at its Richmond, VA location. This anatomic stage i breast cancer ajcc v8 clinical trial is actively enrolling qualified participants.

Is participation in this Richmond clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Anatomic Stage I Breast Cancer AJCC v8 Clinical Trial in Richmond, VA

Q: How do I join the anatomic stage i breast cancer ajcc v8 clinical trial in Richmond?

To join this clinical trial in Richmond, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

About This Anatomic Stage I Breast Cancer AJCC v8 Study in Richmond

This clinical trial studies whether a healthy living intervention (HLI), with or without a physical activity intervention (PAI), helps maintain the ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment. Early detection and enhanced therapies for breast cancer have improved 5-year cancer-related survival rates. Unfortunately, many breast cancer survivors are at high risk for long-term exercise intolerance, decreased heart health, and lower quality of life following chemotherapy. Currently, there are no effective therapies to help patients maintain these areas throughout chemotherapy. The HLI in this study includes virtual health education classes, which provide useful information on topics like proper nutrition, managing stress, and sleep practices. This may help patients understand the importance of living a healthy lifestyle during chemotherapy. The PAI in this study consists of virtual exercise sessions personalized to the needs of the patient, which may make it easier for patients to stay active during chemotherapy. HLI with PAI may be a more effective way to help maintain ability to exercise, heart health, and quality of life in breast cancer patients who are scheduled to receive chemotherapy treatment.

Sponsor: Wake Forest University Health Sciences

Who Can Participate

Inclusion Criteria

Stage I-III breast cancer (including inflammatory and newly diagnosed, or locally recurrent \[if prior treatment received ≥ 2 years prior\] but not metastatic breast cancer being treated with curative intent). All molecular subtypes (estrogen receptor \[ER\], progesterone receptor \[PR\], human epidermal growth factor receptor 2 \[HER2\], etc.) are acceptable

Scheduled to receive neoadjuvant or adjuvant cytotoxic chemotherapy. Patient must be enrolled ≤ 3 weeks from start of cytotoxic chemotherapy

Age 18 to 85 years at enrollment. The upper age cut-off is due to the increased risk of injury in the older population during the CPET, which uses stationary bicycle exercise testing, outweighing the benefit of including this age group

Must be able to complete a stationary bicycle exercise test where you pedal against some resistance on a stationary bike with supervisors at your side per patient self-report

Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting per patient self-report

Able to hold breath for 8 seconds

Must be able to read and understand English language

Must have access to a device that allows teleconferencing (e.g., Zoom calls) or be willing to participate in the Tablet Lending Program

Must be willing to download and use the Trainerize application to their personal device or be willing to participate in the Tablet Lending Program

Must have a working email address to participate in teleconferencing (e.g., Zoom calls). Local National Cancer Institute Community Oncology Research Program (NCORP) site staff may assist in setting up a new email address, if needed

Exclusion Criteria

At enrollment, the following diagnosis and/or conditions may not be present (i.e., documented in the medical record or by patient self-report):

Symptomatic claustrophobia

Pregnancy or breast-feeding

Ferromagnetic cerebral aneurysm clips or other intraorbital/intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices or other implanted non-compatible MRI devices, such as tissue expanders

Uncontrolled hypertension (systolic blood pressure \> 190 mm Hg or diastolic blood pressure \> 100 mm Hg)

Inflammatory conditions such as lupus or inflammatory bowel disease, or another medical condition that might compromise safety or successful completion, as determined by the treating physician

Significant ventricular arrhythmias (\> 20 premature ventricular contractions \[PVCs\]/min)

Atrial fibrillation with uncontrolled ventricular response (\> 130 beats per minute \[bpm\])

Unstable or stable angina (cardiac chest pain)

Severe pulmonary hypertension

Left main coronary artery disease

Symptomatic heart failure

Severe valvular heart disease

Aortic aneurysm (\> 45 mm diameter) or aortic dissection

Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise

Hypertrophic obstructive cardiomyopathy

Acute myocardial infarction within 28 days of enrollment

Acute pulmonary embolus and/or deep vein thrombosis within 24 weeks prior to enrollment

Plans to relocate within 6 months of enrollment and unable to participate in study procedures

May not be on a simultaneous interventional supportive care (non-therapeutic) clinical trial

May not be undergoing simultaneous treatment for a concurrent second primary cancer (patients with historical cancer will not be excluded if chemotherapy was received ≥ 2 years prior)

May not be currently engaged in ≥ 300 minutes of moderate to vigorous intensity physical activity per week as determined by self-report on the International Physical Activity Questionnaire -Short Form (IPAQ-SF). Site should use the IPAQ-SF screener in the REDCap WF-2401 STEPS-BC screening project to assist in this determination

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Richmond?

Yes, this clinical trial (NCT07474090) has an active research site in Richmond, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Anatomic Stage I Breast Cancer AJCC v8 Treatment Options in Richmond, VA

If you're searching for anatomic stage i breast cancer ajcc v8 treatment options in Richmond, VA, this clinical trial (NCT07474090) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Richmond research site is actively enrolling participants for this clinical trial. You'll receive care from experienced anatomic stage i breast cancer ajcc v8 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all anatomic stage i breast cancer ajcc v8 clinical trials near you to find additional studies recruiting in your area.

Anatomic Stage I Breast Cancer AJCC v8 Clinical Trial in Richmond, VA

Expert Care in Richmond

IRB Approved

No-Cost Care

Apply for This Richmond Location

Why Participate?

Simple Process